Simultaneous Thoracic Spine Metastatic Melanoma and Pre-existing Prostate Adenocarcinoma: A Unique Case Presentation and Literature Review.
association: prostate cancer
melanoma and nevi
melanoma primary
melanoma protocol
prostate cancer (pca)
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
accepted:
12
08
2023
medline:
14
9
2023
pubmed:
14
9
2023
entrez:
14
9
2023
Statut:
epublish
Résumé
In melanoma patients, distant metastases frequently manifest in the skin, lung, brain, liver, bone, and intestine. Notably, bone metastasis predominantly occurs within the axial skeleton, with the lumbar and thoracic spines being the most affected regions. Conversely, prostate cancer often disseminates to the bone, lung, liver, pleura, and adrenal glands. The spinal column, particularly the lumbar region, frequently harbors metastases in prostate cancer cases. Given the proximity of axial lesions to the spinal cord, patients commonly experience pain, weakness, and urinary dysfunction. This article presents a compelling case report of a patient initially diagnosed with metastatic prostate cancer, who later exhibited a metastatic lesion in the thoracic spine, subsequently identified as originating from acral melanoma on the plantar surface of the right foot. Histopathological examination confirmed the presence of acral melanoma in both the spine and the right foot. The patient received comprehensive treatment for advanced melanoma from a multidisciplinary team comprising medical and radiation oncologists. Considering the overlapping pathophysiology of prostate cancer and melanoma, simultaneous screening for both diseases in cases where one is detected could yield significant benefits, including enhanced morbidity and mortality outcomes and the facilitation of early detection for secondary malignancies.
Identifiants
pubmed: 37706116
doi: 10.7759/cureus.43429
pmc: PMC10497177
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e43429Informations de copyright
Copyright © 2023, Venkata et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Arch Phys Med Rehabil. 1996 Mar;77(3):307-9
pubmed: 8600878
Int J Environ Res Public Health. 2019 Oct 15;16(20):
pubmed: 31618913
Arch Dermatol. 2010 Mar;146(3):322-4
pubmed: 20231506
N Engl J Med. 2012 Aug 16;367(7):669-71
pubmed: 22894580
Br J Cancer. 2013 Jun 25;108(12):2582-9
pubmed: 23695019
Hum Pathol. 2000 May;31(5):578-83
pubmed: 10836297
Br J Cancer. 2008 Oct 21;99(8):1296-301
pubmed: 18854827
J Surg Res. 2003 Apr;110(2):393-8
pubmed: 12788670
Med Chem. 2008 Mar;4(2):100-5
pubmed: 18336327
Br J Cancer. 2023 Jan;128(1):71-79
pubmed: 36319848
Int J Mol Sci. 2020 Nov 26;21(23):
pubmed: 33256089
Int J Cancer. 2007 Dec 15;121(12):2688-92
pubmed: 17724724
J Clin Oncol. 2013 Dec 10;31(35):4394-9
pubmed: 24190118
JAMA. 2023 Apr 18;329(15):1290-1295
pubmed: 37071089
Cancers (Basel). 2015 Apr 15;7(2):670-8
pubmed: 25884238
Oncogene. 2003 May 19;22(20):3113-22
pubmed: 12789288
Cancer Causes Control. 2008 Mar;19(2):175-81
pubmed: 18027095
Int J Cancer. 2015 Dec 15;137(12):2795-802
pubmed: 25557753
Cancer Res. 2003 Jun 1;63(11):2881-90
pubmed: 12782594
Lancet. 2014 Dec 6;384(9959):2027-35
pubmed: 25108889
Eur Urol. 2012 Nov;62(5):745-52
pubmed: 22704366
Medicine (Baltimore). 2019 Feb;98(5):e14107
pubmed: 30702565
Nat Rev Cancer. 2011 Apr;11(4):289-301
pubmed: 21430697
BMJ. 2018 Sep 05;362:k3519
pubmed: 30185521
Front Oncol. 2021 May 19;11:644885
pubmed: 34094931
Prostate Cancer Prostatic Dis. 2022 Sep;25(3):479-483
pubmed: 34294873
J Natl Cancer Inst Monogr. 2000;(27):39-66
pubmed: 10963619
Cancer. 2017 Feb 15;123(4):592-599
pubmed: 27911486
Cancer Biol Ther. 2019;20(11):1366-1379
pubmed: 31366280
Cells. 2021 Sep 05;10(9):
pubmed: 34571969
Melanoma Res. 2018 Dec;28(6):562-570
pubmed: 29975212